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Abstract
The presence of islet autoantibodies (iAbs) is currently the most reliable biomarker for 
type 1 diabetes (T1D). The current “gold” standard radio-binding assays that measure 
four major iAbs to insulin, IAA, GAD65, IA-2A and ZnT8, are laborious and do not fit 
for large-scale screenings. Around 40% of patients with T1D develop other autoimmune 
diseases like celiac disease, autoimmune thyroid disease, and so on. It is highly recom-
mended to screen these closely related autoimmune diseases during T1D screening; how-
ever, there is no method available. Recently, on the platform of extensively validated 
high-sensitive and high-specific electrochemiluminescence (ECL) assay, we developed 
a multiplex ECL assay to combine up to 10 autoantibody assays into one single well 
with 5 μl of blood sample. It not only allows us to combine multiple iAbs into one but 
also makes it possible to simultaneously screen T1D and other multiple autoimmune 
diseases, which in turn facilitates large-scale screenings in the general population.
Keywords: autoantibody, autoimmune disease, type 1 diabetes, electrochemiluminescence, 
multuplex assay
1. Introduction
Type 1 diabetes (T1D), the immune-mediated form of diabetes [1], is increasing worldwide, 
3–5% annually [2], with rates doubling every 20 years [3, 4], especially in young children. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In the USA, 1.4 million people have T1D and as many have multiple islet autoantibodies 
(iAbs) or pre-T1D with normal glucose homeostasis. Of the latter, 84% will progress to clini-
cal diabetes in 15 years with a remarkable consistency across populations [5]. Although T1D 
is a T-lymphocyte-mediated autoimmune disease with specific destruction of pancreatic islet 
β-cells, autoantibodies directed against proteins in insulin-producing beta cells [1] are the best 
biomarkers for risk prediction and clinical diagnosis. These iAbs usually appear years before 
overt clinical disease, and the presence of ≥2 iAbs [antibodies-directed against insulin (IAA), 
glutamic acid decarboxylase (GADA), islet antigen 2 (IA-2A) or zinc transporter 8 (ZnT8A)] 
predicts the development of clinical T1D in nearly all affected children [5]. Children at risk 
for T1D need to be identified prior to the onset of symptoms to: (1) prevent life-threatening 
diabetic ketoacidosis, (2) identify individuals for current and upcoming trials to prevent T1D 
and (3) define the onset of islet autoimmunity and its triggers.
Appearance of iAbs is currently the most reliable marker of the autoimmune process lead-
ing to T1D, and it determines the disease risk and marks the onset of autoimmune beta 
cell destruction. The presence of iAbs, their number [6–8] and titer [9–11], has being used 
extensively to stage diabetes risk and as inclusion criteria into T1D prevention trials [12]. 
Immunoassays to detect iAbs can be classified into four generations. The first generation is 
the indirect immunofluorescence on cryostat sections of the pancreas for islet cell antibodies 
(ICA) [13, 14] present in patients’ sera to a variety of autoantigens in islet β-cells. This assay 
requires the pancreas tissue to conduct the measurement and is very limited in the regular 
screening. The second generation of iAbs immunoassays is a well-established radio-binding 
assay (RBA) which is based on various biochemically defined autoantigens and plays a major 
role as the current gold standard assay for all four major islet autoantibodies IAA, GADA, 
IA-2A and ZnT8A and ELISAs. Traditional ELISA has been proved not to work well for 
any iAbs with less sensitivity and less specific in multiple workshops of Islet Autoantibody 
Standardization Program (IASP, previously DASP). However, a modified bridging ELISA 
with semifluid-phase interaction between the antibody and antigen has achieved sensitiv-
ity and specificity equivalent to the RBA for the measurement of GADA, IA-2A and ZnT8A 
[15–19]. The third generation is a recently developed and extensively validated nonradio-
active iAb assay using electrochemiluminescence (ECL) detection with a higher sensitiv-
ity and higher disease specificity compared to the RBAs [20–25]. The ECL assay has been 
demonstrated to be more sensitive and is able to identify the first iAb of “seroconversion” 
earlier than RBA by years in young children followed from the birth on pre-T1D who were 
followed to clinical diabetes. More remarkably, ECL assay is able to discriminate high-affin-
ity, high-risk autoantibodies from those “low risk,” low-affinity signals generated by RBA 
in subjects with single iAb who are less likely to progress to T1D. The fourth generation of 
autoantibody immunoassays is to develop a simple multiplexed assay to fit for the needs 
of ongoing and future clinical trials to simultaneously screen multiple iAbs and other auto-
antibodies in one single well, which will facilitate high-throughput autoantibody screening 
simultaneously for T1D and other multiple relevant autoimmune diseases in large scale of 
populations. ECL assay has been illustrated as an excellent platform for a simple multiplex 
assay with a superior advantage of high sensitivity and disease specificity. In this chapter, 
we mainly focus on the discussion of: (1) two currently most popular assays for iAbs, a gold 
standard RBA and a modified bridging ELISA; (2) ECL assay and its comparison with RBA 
and (3) development of a simple multiplex ECL assay with all advantages considered.
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2. Radio-binding assay (RBA) and enzyme-linked immunosorbent 
assay (ELISA)
At present, four major biochemically defined β-cell autoantigens were well characterized 
including IAA [26], GAD65 [27], IA-2 [28] and ZnT8 [29]. Through laboratory proficiency 
programs [30, 31] and harmonization efforts [32], RBA, a fluid-phase assay using radiola-
beled antigens and precipitating antibody-antigen complex by Protein A/G Sepharose, has 
been well established as a current “gold” standard assay for autoantibodies to all four major 
antigens [29, 32, 33].
In RBA, recombinant human insulin is labeled with I-125, while GAD, IA-2 and ZnT8 anti-
gens are expressed from their corresponding recombinant human cDNA and labeled with 
35S-methionine by coupled in vitro transcription/translation. To assess general implemen-
tation of assay methods and to standardize the iAb assays, the Center for Disease Control 
and Prevention (CDC) and Immunology and Diabetes Society (IDS) started organizing the 
Diabetes Autoantibody Standardization Program (DASP) workshop in the year of 2000 [34]. 
Forty-six laboratories in 13 countries participated in the program. The first proficiency evalu-
ation of DASP showed a high concordance in measurement of GADA (r = 0.96; p < 0.0001) and 
IA-2A (r = 0.89; p < 0.0001) using the new WHO international reference reagent. In contrast, 
the workshop demonstrated wide variation among IAA assays, with poor overall perfor-
mance and low sensitivity. IAA assays were improved after the first proficiency evaluation 
and the median laboratory assigned sensitivity was 26, 36 and 45% in 2002, 2003 and 2005, 
respectively (p < 0.0001). However, the IAA assay has proven the most difficult to standardize 
with relatively wide discrepancies between laboratories in the IASP workshop and has not yet 
achieved a satisfactory level of sensitivity and specificity. There was still remarkable variation 
between laboratories and the ranking of IAA levels in patient serum samples was concordant 
to AUC (p < 0.001), and the AUC ranged from 0.36 to 0.91 [30]. To facilitate comparison of 
quantitative islet autoantibody results between studies, the National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK) set up an Islet Autoantibody Harmonization 
Committee in 2007 to align measurement and reporting of iAbs in all NIDDK-sponsored 
studies and several different central laboratories are used [32]. With a few years of combined 
efforts, both GADA and IA-2A assays were successfully harmonized with great concordance 
as positive or negative between participating laboratories. The IA-2A assay, using a common 
threshold of 5 DK units/ml, achieved 64% sensitivity with specificity greater than 99% in all 
laboratories. For GADA, using thresholds equivalent to the 97th percentile of 974 control 
samples in each laboratory, 1051 (97.9%) of 1074 samples were concordant. ZnT8 is a most 
recently identified new islet β-cell autoantigen, and ZnT8A assay has been well established 
through IASP workshop. In combination of current four iAb assays by the standard RBA, the 
overall sensitivity is able to cover around 95% in newly diagnosed patients with T1D [29]. 
To lead to more reproducible identification of individuals at risk of type 1 diabetes and 
improve monitoring in long-term prospective studies, some recommendations by the Islet 
Autoantibody Harmonization Committee have been applied to current national and inter-
national clinical trials for T1D: (1) confirmation of positive results in a second laboratory is 
likely to be valuable to identify discrepancies; (2) laboratories should use common calibrators 
against reference standards; (3) the methods used in multiple centers should be compared 
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and harmonized to eliminate potential factors that will contribute to discrepancies; (4) a com-
mon set of samples which can provide knowledge of concordance, sensitivity and specificity 
including a large number of samples from healthy controls, and patients should be identi-
fied to establish working thresholds of positivity that are similar between the participating 
laboratories.
T1D is now able to be predicted by measuring iAbs present in the peripheral blood, and these 
iAbs have been used to determine disease risk and onset of autoimmune beta cell destruction. 
Almost all children with two or more of these iAbs will progress to clinical diabetes with a 
remarkable consistency across populations, while progression to diabetes in children persis-
tently positive for a single iAb is only 15% in 15 years [30], as most of these children have a 
low-affinity iAb not associated with disease [35–37].
In summary, the current method most commonly used for screening iAbs is the “gold” standard 
RBA, a fluid-phase assay using radiolabeled antigens and immunoprecipitation, to quantify 
four major iAbs named IAA, GADA, IA-2A and ZNT8A. These four RBAs are currently able 
to cover 95% of sensitivity in newly diagnosed patients with T1D. Through the efforts of iAb 
proficiency programs and harmonization consortia, current standard RBA for iAbs have been 
greatly improved, but there are still work to be done, especially (1) IAA is not achieved its sensi-
tivity and specificity and (2) there is a low risk prediction in subjects with single iAb positivity.
A direct enzyme-linked immunosorbent assay (ELISA) format (binding of antigen to plate 
and detection of bound autoantibody with labeled anti-antibodies) has proven difficult to 
develop. To date, only one ELISA-based ElisaRSR™ for GADA, IA-2A and ZnT8A, distributed 
by Kronus that utilizes capture of solution-phase antigen by one chain of immunoglobulin 
(Ig) while being bound by its other chain to plate-bound antigen has demonstrated sensitivity 
and specificity similar to the fluid-phase RBA (www.rsrltd.com). But there is no any ELISA-
based assay that works well for IAA measurement according to IASP workshop [30]. ELISA 
assays were found only to detect insulin antibodies induced by exogenous insulin injection 
[38], but not natural insulin autoantibodies. Our group reported a high sensitive ELISA-based 
competition Europium IAA assay in 2009 [39], and it worked very well for mouse IAA assay, 
but unfortunately it did not work at all for human samples, although RBA-IAA assay works 
equally well for both human and mouse samples [33].
3. Electrochemiluminescence (ECL) assays
While the current standard RBA for iAbs has been greatly improved through the labora-
tory proficiency programs and harmonization efforts, there are still works in progress. The 
IAA assay, especially, has not yet achieved a satisfactory level of sensitivity and specificity. 
Importantly, IAA has a high prevalence among young children [36] and is usually the first 
iAb to appear in young children [37]. The ability of prospective clinical studies, for example, 
The Environmental Determinants of Diabetes in the Young (TEDDY), which aims to identify 
triggers of islet autoimmunity, depends on accurate detection of the timing of appearance of 
the first iAb to mark the very beginning of islet autoimmunity. We have recently developed 
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and extensively validated a new generation of nonradioactive iAb assay using ECL detection, 
as we described in the previous section, with an excellent sensitivity and specificity [20–25] 
for both IAA and GADA. The assay is based on the principle that interaction of autoanti-
bodies with antigen molecules is in liquid phase, and the detection signals are directly from 
the labeled antigen molecules bound to specific autoantibodies without applying the labeled 
second antibody (labeled anti-human IgG antibody usually used in conventional ELISA) for 
detection, which usually causes a very high background in autoantibody assays with human 
samples. As illustrated for ECL assay protocol in Figure 1, autoantibodies in serum help 
bridge the Sulfo-tagged antigen molecule to the biotinylated antigen molecule, which will 
be captured on the solid phase of the streptavidin-coated plate. Detection of plate-captured 
Sulfo-tagged antigen is accomplished with electrochemiluminescence. The fact that the ECL 
assay is able to capture all immunoglobulin subgroups no matter IgG, IgM, IgA or IgE allows 
this assay a higher sensitivity than current standard RBA based on IgG detection. With the 
new ECL assays, we have analyzed thousands of participants in Diabetes Autoimmunity 
Study in the Young (DAISY) [21], TrialNet Pathway to Prevention subjects [23] and very 
recently TEDDY subjects (unpublished data). Compared with gold standard RBA, the ECL 
assays, especially ECL-IAA assays, were demonstrated more sensitive. In DAISY longitudi-
nally follow-up study, we analyzed 427 sequential samples from 63 pre-T1D who were closely 
followed to clinical T1D. Nearly all of these children (62/63) were detected ECL-IAA years 
before disease onset, including 10 children who were completely IAA negative by RBA-IAA 
during the follow-up. Remarkably, 25% of these early longitudinally followed samples during 
Figure 1. Illustration of the bivalent plate capture ECL assay. The antibody in serum will link the Sulfo-tagged antigen to 
the biotinylated antigen, which will be captured on the solid phase of the streptavidin-coated plate. Detection of plate-
captured Sulfo-tagged antigen is accomplished with electrochemiluminescence.
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pre-diabetes stage which were positive for ECL-IAA were negative for RBA-IAA (Figure 2). 
ECL-IAA were found to antedate the onset of islet autoimmunity in these children by a mean 
of 2.3 years (range: 0.3–7.2 years) [21]. The earlier identification of IAA among young chil-
dren was validated from a later TEDDY study cohort (unpublished data). Results from these 
studies indicate that this novel ECL-IAA assay is not only more sensitive but also defines the 
timing of the initial autoantibody appearance earlier than the previously used RBA-IAA. This 
earlier detection and accuracy in timing of onset of islet autoimmunity in young children fol-
lowed from the birth is important to find potential environmental causes of diabetes and our 
understanding of the etiology of T1D as the ability to identify triggers of islet autoimmunity, 
for example, TEDDY study depends on the sensitivity and validity of iAb assays used to pin-
point the “seroconversion” to islet autoimmunity.
Remarkably, both ECL-IAA and ECL-GADA assays were selectively detecting the positivity 
from the high-risk subjects who were followed to progression of clinical T1D or the subjects 
who were multiple iAbs positive. In the study of DAISY children [20, 22], we analyzed all 
pre-T1D children who were followed to clinical diabetes and all non-diabetic children who 
were persistently iAbs positive, either multiple iAbs or single iAb, and compared them with 
RBA. Almost all samples positive by RBA (IAA or GADA) were ECL assay positive in children 
on pre-T1D or children with presence of multiple iAbs. In contrast, only around 25% of non-
diabetic children with either single IAA or single GADA positive by RBA were ECL positive. 
Figure 3 shows positivity of IAA among some children in the DAISY study as an example, per-
sistently expressing IAA with other iAbs (multiple iAbs) or as a single iAb. Panel A: ECL-IAA 
Figure 2. IAA identification in pre-diabetic children by ECL-IAA. The x-axis represents results of ECL-IAA assay and 
the y-axis represents results of mIAA RIA assay. About 25% of pre-diabetic samples were positive for ECL-IAA  but 
negative for mIAA RIA assay.
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was well correlated with RBA-IAA for all five subjects (multiple follow-up positive for both 
assays), who were multiple iAbs positive. Panel B: 7/8 subjects with single iAb (IAA only) were 
consistently ECL-IAA negative. The antibody affinity study was performed to compare these 
IAA or GADA detected by RBA, but differentiated by ECL assay as positive or negative. The 
results of affinity analysis discovered that IAA or GADA detected by RBA, but negative with 
ECL assay, in children who were absent of other iAbs had low affinity, while IAA or GADA 
positive by both RBA and ECL assays had high affinity. Figure 4 illustrates the IAA (panel A) 
or GADA (panel B) competition assays with unlabeled proinsulin or GAD65 protein. The IAA 
or GADA not detected by the ECL assay required a 10- to 100-fold higher concentration of 
unlabeled insulin/proinsulin or GAD65 protein for 50% inhibition of binding of IAA or GADA 
to labeled insulin or GAD65 protein. These results demonstrated that both ECL-IAA and ECL-
GADA were able to discriminate high-affinity, high-risk iAbs from those “low risk,” low-affin-
ity signals generated by RBA in subjects who are less likely to progress to T1D. In our later 
validation study with a large TrialNet cohort of Pathway to Prevention, identical results were 
obtained [23] by characteristics of disease specificity with both ECL-IAA and ECL-GADA. The 
study analyzed 3500 subjects in blind with 571 multiple iAbs, 1727 single iAb and 384 pre-T1D 
who were followed to clinical T1D later in the study. The ECL assay and RBA were found con-
gruent in pre-diabetics and in the subjects with multiple autoantibodies, but only 24% of single 
RBA-IAA (p < 0.0001) and 46% of single RBA-GADA (p < 0.0001) were confirmed by the ECL-
IAA and ECL-GADA assays, respectively. With the prospective following up for the subjects 
with single IAA or GADA, 51% of RBA-IAA and 63% of RBA-GADA subjects not confirmed 
by ECL were found lost their iAbs and became iAb negative after a mean follow-up time of 
2.4 years, behaving as “transient” iAb positivity. Only a few subjects converted to multiple 
iAbs or progressed to clinical diabetes. In contrast, only small percentages of RBA-IAA and 
RBA-GADA confirmed by ECL assays became negative (p < 0.0001 for both IAA and GADA) 
during the follow-up as significant number of subjects progressed to clinical diabetes or multi-
ple iAbs. In the study, 2944 subjects were studied with their very first initial screening samples 
Figure 3. Sera from children in the DAISY study persistently expressing IAA as a single or with multiple iAbs were 
analyzed with the ECL-IAA assay. Panel A: ECL-IAA was well correlated with RBA-IAA for all 5 subjects (multiple 
follow-up positive for both assays) who were multiple iAbs positive. Panel B: 7/8 subjects with single iAb (IAA only) 
were consistently ECL-IAA negative.
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and prospectively followed to clinical T1D during the study period. The positive and negative 
predictive values of RBA and ECL assays, in terms of progression to T1D, were analyzed and 
compared, and the data are illustrated in Figure 5. The positive predictive values for ECL-IAA 
and ECL-GADA were 32 and 24%, significantly higher than those RBA-IAA and RBA-GADA 
(21 and 16%, respectively; both p < 0.0001) (panel A). Similarly, the negative predictive values 
for ECL-IAA and ECL-GADA were 94 and 96%, significantly higher than those for RBA-IAA 
and RBA-GADA (92%; p < 0.05 and 94%; p = 0.007, respectively) (panel B). Compared with 
HLA analysis, the highest risk genotype for T1D, HLA-DR3/4, DQB1*0302 was significantly 
higher in subjects with IAA or GADA confirmed by ECL than those not confirmed by ECL 
assays (p < 0.0017 and p < 0.0001, respectively). The frequency of this high-risk HLA genotype 
in subjects with either single IAA or GADA not confirmed by ECL assays was found identical 
to subjects with negative results for all iAbs, a very low-risk population who are very unlikely 
to progress to T1D.
Autoantibody affinity in sequential follow-up samples from their initial positive screening to 
their later follow-up with a mean follow-up of 5.3 years were investigated [25] in a subset 
of subjects in TrialNet Pathway to Prevention study who were persistent single RBA-IAA or 
single RBA-GADA positive confirmed or not confirmed by ECL assays. Among either single 
IAA or single GADA subjects, all subjects who were confirmed by ECL assays were found to 
have high affinity autoantibodies at their very first initial positive visit. Affinity results stayed 
consistent over time. Similarly, those who were negative for ECL assays showed lower affinity 
at initial visit and affinity stayed low over time. No converting events from low to high or high 
Figure 4. Illustration of the IAA (Panel A) or GADA (Panel B) competition assays with unlabeled proinsulin or GAD65 
protein. IAA /GADA negative by ECL-IAA / ECL-GADA assay (blue line), compared with IAA /GADA positive by ECL-
GADA/ECL-IAA assay (red line), and required higher concentrations of unlabeled insulin/proinsulin or GAD65 protein 
for 50% maximal inhibition, which is consistent with low affinity.
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to low affinity were seen over time. There were 14 subjects in the group who progressed to 
clinical T1D during the study period. All except one were ECL-positive and had a high affinity 
for IAA or GADA. These results implicate that a more disease-specific iAb measurement like 
ECL assay can identify high affinity iAbs with high disease risk on the early stage of initial 
screening. It is generally assumed that the very low risk of those with only a single iAb, either 
single IAA or single GADA, spreading of autoimmunity to other autoantigens is needed to 
increase risk or marks a stage closer to overt diabetes, and multiple studies of both relatives of 
T1D patients and general populations have documented that expression of multiple iAbs are 
associated with extreme risk of progression to T1D. The pattern of expression of iAbs detected 
by ECL assays predicts both epitope spreading and diabetes risk. Differences in iAbs reactiv-
ity can be assessed prior to epitope spreading consistent with early determination of both 
Figure 5. Predictive values of IAA and GADA assays in the TrialNet Initial Screening study. A: Positive predictive values 
of RIA-IAA and ECL-IAA assays, RIA-GADA and ECL-GADA assays. B: Negative predictive values of RIA-IAA and 
ECL-IAA assays, RIA-GADA and ECL-GADA assays. Positive and negative predictive values of ECL-IAA and ECL-
GADA were significantly higher than those of RIA-IAA and RIA-GADA assays, respectively.
RBA positive, GADA only RBA positive, IAA only
ECL+ (n = 107) ECL− (n = 78) p-value ECL+ (n = 24) ECL− (n = 63) p-value
PS6M (mg/dl) 22 ± 90 −19 ± 71 0.001 36 ± 75 −9 ± 70 0.009
Progressed to T1D 14.0% (n = 15) 1.3% (n = 1) 0.002 16.7% (n = 4) 0% (n = 0) 0.005
PS6M is a 6-month progression scale based on worsening of the 30–120-min OGTT glucose.
Table 1. ECL iAb identify progressors to T1D among children and adults with single iAb by RBA.
Development of a Simple Multiplex Electrochemiluminescence (ECL) Assay for Screening Pre…
http://dx.doi.org/10.5772/intechopen.75515
197
epitope spreading and diabetes risk. This is of particular value in children and young adults 
who are positive for a single iAb, as demonstrated by TrialNet Pathway to Prevention (Table 1, 
J Sosenko, manuscript submitted). Among TrialNet participants who were positive for a single 
iAb by RBA, 52% (141/272) were not confirmed by ECL. These ECL-negative subjects showed 
no worsening of glycemia and little progression to T1D during a median follow-up of 4.7 years. 
In contrast, OGTT glycemia worsened significantly in the ECL-positive single iAb partici-
pants, comparably with the worsening in 90 multiple iAb + subjects (PS6M 23 ± 96 mg/dl); 
the latter group had a high risk for progression to T1D (30%). The ECL assay can substan-
tially refine the selection of single iAb positive individuals at high risk, who possibly could be 
recruited for participation in T1D prevention trials.
Presently, clinical prevention trials in T1D TrialNet study are only selecting relatives of 
patients with T1D who have multiple iAbs. It is generally agreed that some clinical interven-
ing on early stages of islet autoimmune processes could result in a better outcome as some 
evidence in animal model for prevention [40], but the clinical trial studies using subjects with 
single iAb, either single IAA or GADA, are not available since the risk is too low. However, 
the subjects with single iAb (IAA or GADA) detected by more disease-specific assays like ECL 
assay with the nature of ability to detect high affinity antibodies may qualify for enrollment 
into prevention trials as their risk for diabetes is much higher and those with low affinity, 
low-risk signals generated by RBA will be removed [20, 22, 23, 25]. On the other hand, sub-
jects found to be negative for ECL assays may benefit from less intensive monitoring in these 
longitudinal prospective studies [41] to save the efforts and costs of these studies.
In summary, islet autoimmunity of T1D can be identified at the very beginning of the disease 
process by measurements of iAbs. Two major iAbs, IAA and GADA, usually appear earlier 
than other iAbs and are often detected in isolation as single iAb in the screening of relatives 
and general population. Most of these single iAbs detected by current gold standard RBA are 
at low risk, low affinity and non-disease relevant as “biologically” false positives while part 
of these single iAbs does represent the early stage of islet autoimmunity in T1D progression. 
With more disease-specific assays like an ECL assay method, high-risk and disease-relevant 
iAbs are able to be identified at the very beginning of the disease process in subjects with 
single iAb before the development of multiple iAbs closer to overt clinical diabetes, which 
will be greatly appreciated for clearing the current confusions of single iAb positivity and aid 
the T1D clinical trials for both identifying environmental triggers of islet autoimmunity and 
intervening with islet autoimmune process on very beginning stage to prevent the disease. 
The ECL assay was demonstrated its superiority to RBA in sensitivity and especially ECL-
IAA was able to antedated the onset of islet autoimmunity by years than RBA, which will be 
very important to accurately pinpoint the very beginning of islet autoimmunity for identify-
ing the environmental triggers to cause the T1D.
4. Development of a multiplex assay for large-scale screening
At present, many large-scale national and international clinical trials for T1D are in progress, and 
multiple candidate interventions are being proposed to abrogate or slow progression of T1D 
among iAb positive subjects. A wider screening of iAbs in the general population, especially 
in young children, is perspectively in progress or in planning. Currently, four biochemically 
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defined iAbs including IAA, GADA, IA-2A and ZnT8A are equally important in prediction and 
evaluation of risk of progression to T1D in both relatives of patients with T1D and general popu-
lation. The screening methods using current standard RBA with single iAb measurement are 
laborious and inefficient for such a large scale of screening. While significant progress has been 
made in standardization of iAb assays and high-throughput technologies, the cost and logis-
tic complexity of currently used methods preclude their widespread use in population-based 
screening. The determination of initial iAb positivity is very important, which may represent 
the initiation of islet autoimmunity. However, the results of iAb measurement at this early stage 
in subjects with a single iAb are not reliable with current standard RBA since the majority of 
these single iAb subjects identified by RBA have low affinity antibodies, most of them transient, 
and therefore biologically appear to be “false positives” with respect to T1D development as 
we discussed earlier. Poor assay specificity is likely to be more problematic for screening pro-
cess in general population with lower frequency of risk for T1D than high risk relative cohort 
as in TrialNet Pathway to Prevention we studied. A high-throughput assay technology with 
improved disease specificity will be important and necessary.
One in four children at risk for T1D develops islet, celiac, thyroid or rheumatoid autoimmunity 
in the DAISY study. Interestingly, there is little overlap of these phenotypes in an individual 
child, but this overlap increases with age. The incidence of autoantibodies to thyroid peroxi-
dase (TPOA) surges after the age of 12. Importantly, up to 40% of patients with T1D have an 
additional autoimmune condition [42–44]. It is important and urgent to screen biomarkers of 
other autoimmune diseases when screening diabetes, simultaneously. Unfortunately, there is 
no easy and inexpensive tool to screen for these conditions. With a big effort, all DAISY and 
TEDDY study participants are screened for autoantibodies to tissue transglutaminase (TGA) 
for celiac disease autoimmunity. Persistent TGA positivity and celiac disease are secondary 
endpoints in both studies [45, 46]. DAISY data suggest that, by age 18, at least 7% of the general 
population persistently express one or more of the nine autoantibodies: IAA, GADA, IA-2A, 
ZnT8A, TPOA, TGA and three other autoantibodies for rheumatoid arthritis, Addison’s dis-
ease and autoimmune gastritis. If confirmed, this would argue for a universal screening. We 
have carried out a pilot of such screening for iAbs and TGA, in children of 2–6 years old attend-
ing general pediatric care offices in Denver [47]. Participating parents and providers ranked the 
combined screening for iAbs and TGA as more valuable than screening for iAbs alone.
To fit the purpose of large-scale screening in national clinical trials and the general popula-
tion, people are starting to seek a possible method of a multiplexed assay combining multiple 
autoantibody assays together in one single well. Recently, a few studies of multiplex antibody 
assays were reported with different technologies [48–51], but none of these assay platforms 
has neither compared with currently used “gold” standard RBA for its sensitivity and speci-
ficity in T1D study, especially in subjects with risk to T1D, nor validated in an international 
Islet Autoantibody Standardization Program (IASP) workshop or in a large cohort of clini-
cal trial. From previous multiple studies, none of the conventional ELISA methods worked 
well for any iAb measurements, especially for IAA according to multiple IASP workshop 
[30]. Interaction of iAbs with their corresponding antigen proteins in liquid phase will still 
be necessary in a multiplex assay setting to achieve a proper sensitivity and specificity and 
it is a particularly essential condition for IAA assay. The capacity of specific autoantibody-
antigen binding might be a new consideration with our recent experiences in a multiplex 
assay setting, which has never been an issue in any single antibody assay format. Multiple 
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autoantibody-antigen interactions share the space within one single well in a multiplex assay 
setting, and each of these interactions might need enough number of their own specific anti-
bodies binding to their corresponding antigen proteins to generate a signal strong enough 
to be detected, which is particularly important when these autoantibodies are at low levels.
Very recently, a modified ELISA-based ElisaRSR™ 3-Screen ICA™ is now available for research 
from the RSR Limited (3-Screen ICA™ ELISA; www.rsrltd.com). It is a combination assay for 
measuring GADA, IA-2A and ZnT8A. Its single assay platform was validated at multiple IASP 
workshops for its sensitivity and specificity. The 3 Screen ELISA assay measures three autoan-
tibodies either in three separate wells consuming large volume of serum or in one single well 
with three assays mixed not able to distinguish which of the three beta cell autoantibodies are 
present. The biggest disadvantage of the 3 Screen ELISA is its inability to include IAA measure-
ment in the assay. IAA has a very high rate of positivity in young children and is considered 
as the first iAb on early stages of islet autoimmunity as we discussed earlier. Compared with 
current single iAb RBA or original single ELISA-based ElisaRSR™ assays, the 3 Screen ELISA 
assay definitely has its advantage of higher efficiency [52], but screening with its own without 
including IAA measurement will be a big defect and will not be the best way to persume.
With the platform of our newly established ECL assay technology, we recently pub-
lished our study of a multiplex assay to accurately measure four autoantibodies in one 
single well [53] with MesoScale Discovery (MSD) QuickPlex 4-Spot plate as illustrated in 
Figure 6. Illustration of ECL 4-spot assay. The 4-spot assay is based on the same mechanism of single ECL assay. Each 
biotinylated antigen will be linked by its corresponding linker which will be captured on the solid phase of the pre-
coated plate. Detection of plate-captured Sulfo-tagged antigen is also accomplished with electrochemiluminescence. 
4-spot assay is able to accommodate up to 4 autoantibody assays in one well.
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Figure 6. The 4-plex assay was based on the same mechanism of our single ECL assay, 
but linker system was introduced. Four interactions of antibody-antigen are, respec-
tively, restrained on each of four specific linker spots within the same well, and the cam-
era is able to catch the signals from four different sources of spots, respectively. With the 
limitation of four spots able to accommodate maximum four autoantibody assays in one 
well, we selected, on purposely, IAA, GADA, IA-2A and TGA. We included TGA instead 
of ZnT8A because (1) ZnT8A is almost always present with other iAbs and ZnT8A alone 
is only 1% in subject followed to T1D (8). In two large national clinical trials of TrialNet 
and TEDDY, ZnT8A is not included in intial screening, and the ZnT8A assay is only 
performed if any of other three iAbs is positive. (2) We want to screen both T1D and 
celiac disease as we rationaled earlier. The 4-plex assay retained 100% sensitivity and 
100% specificity for all four autoantibodies in terms of positivity identified in patients 
versus normal controls compared to the corresponding standard RBA and our single 
ECL assays. In early 2015, MSD company released the new U-Plex™ Development Packs 
system for creating custom multiplex panels of analytes to replace the QuickPlex 4-Spot 
system. With a similar principle of multiplex assay mechanism of QuickPlex 4-Spot sys-
tem, this new system expanded multiplexing up to 10, combining 10 different autoan-
tibody assays in one single well with the same amount of 6 μl serum sample used for a 
single ECL assay. The UPlex plate assay system is illustrated in Figure 7 as we currently 
used it as an UPlex 8-plex assay. With this new system, we have successfully combined 
eight autoantibody assays within one single well including all four iAbs and four other 
Figure 7. Illustration of UPlex 8-plex plate working chart. 8-plex assay is working on the same mechanism of 4-spot 
assay. Uplex can combine up to 10 antibody assays in one well.
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autoantibody assays, TGA for celiac disease, TPOA and autoantibodies to thyroid globu-
lin (ThGA) for autoimmune thyroiditis, autoantibodies to interferon alpha (IFNaA) for 
autoimmune polyglandular syndrom-1 (APS-1). With 100th percentile of specificity in 
118 healthy normal controls, the 8-plex assay was able to retain 100% sensitivity for all 
autoantibodies, and the levels of autoantibodies in 8-plex assay were well correlated 
with their corresponding single RBA or ELISA (for IFNaA) in 168 T1D patients. The 
further work of assay optimization needs to be done to minimize the interferences of 
cross-talking between spots, especially an extreme high signal on one spot overspilled 
to a neighboring spot when it should be negative. The UPlex system made it possible 
to customize a multiplexed assay according to the needs for screening. It is capable to 
screen children simultaneously for T1D and other multiple autoimmune diseases often 
happening in childhood. It is also capable to screen adults simultaneously for T1D and 
other multiple autoimmune diseases usually seen in adulthood. Such a multiplex ECL 
assay technology will retain high assay sensitivity and disease specificity as we dis-
cussed earlier and provide a great tool for a large scale of screening in the general popu-
lation with high efficiency and low cost using only a tiny amount of blood sample. We 
expect these multiplex assays with new technologies, be available in clinic and easily 
applied for population screening in the near future.
In conclusion, T1D is now predictable by measuring major iAbs. The ECL assay for iAbs is 
superior to the current gold standard RBA and other methods in terms of assay sensitivity and 
specificity for disease risk prediction. With a rapid increasing rate of disease, large scales of 
population screenings are becoming important for the public health. Large percent of patients 
with T1D develop other autoimmune diseases, and it has been recommended to screen other 
relevant automimmune diseases when screening diabetes autoimmunity simultaneously. 
With the advantages of the ECL assay in its nature of high assay sensitivity and high disease 
specificity, a simple multiplex assay built on the platform of ECL technology will provide an 
excellent tool to not only screen multiple iAbs in one single well, but also screen multiple auto-
immune diseases simultaneously in large scale of populations efficiently and economically.
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